Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2011-08-09
2011-08-09
Chong, Yong S. (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S529000, C514S546000
Reexamination Certificate
active
07994219
ABSTRACT:
Methods to cause tissue, such as mucosal cells, to express increased amounts of bactericidal permeability increasing protein (BPI) are described. The BPI inducing agents include, for example, lipoxin compounds.
REFERENCES:
patent: 4560514 (1985-12-01), Samuelsson et al.
patent: 4576758 (1986-03-01), Morris
patent: 4780281 (1988-10-01), Marnett et al.
patent: 5049681 (1991-09-01), Sato
patent: 5079261 (1992-01-01), Serhan et al.
patent: 5322699 (1994-06-01), Wright et al.
patent: 5441951 (1995-08-01), Serhan
patent: 5648512 (1997-07-01), Serhan
patent: 5650435 (1997-07-01), Madara et al.
patent: 5998487 (1999-12-01), Brahms et al.
patent: 6329425 (2001-12-01), Madara et al.
patent: 62-198677 (1987-09-01), None
patent: 63-88153 (1988-04-01), None
patent: 1-228994 (1989-09-01), None
patent: 3-227922 (1991-10-01), None
patent: WO 94/29262 (1994-12-01), None
patent: WO 95/01179 (1995-01-01), None
patent: WO 98/11049 (1998-03-01), None
patent: WO 00/13685 (2000-03-01), None
patent: WO 00/54767 (2000-09-01), None
patent: WO 00/55109 (2000-09-01), None
patent: WO 01/60778 (2001-08-01), None
patent: WO 01/70664 (2001-09-01), None
patent: WO 03/039533 (2003-05-01), None
patent: WO 03/051350 (2003-06-01), None
Corey, et al., “On the Synthesis and Structure of Lipoxin B”, Tetrahedron Letters, vol. 26, No. 16, (1985) pp. 1919-1922.
Takano, et al., “Neutrophil-mediated Changes in Vascular Permeability Are Inhibited by Topical Application of Aspiring-triggered 15-epi-lipoxin A4 and Novel Lipoxin B4”, J. Clin. Invest. The American Society for Clinical Investigations, Inc., vol. 101, No. 4, 1998, pp. 819-826.
Nguyen, et al. “Nonsteroidal anti-inflammatory drug use in dentistry: Gastrointestinal Implications”, Pharmacology, Nov. 1999, pp. 590-596.
Maddox, et al., “Lipoxin B4 Regulates Human Monocyte/Neutrophil Adherence and Motility: Design of Stable Lipoxin B4 Analogs with Increased Biologic Activity”, The FASEB Journal, vol. 12, Apr. 1998, pp. 487-494.
Pouliot M., et al, “Lipoxin A4 and Aspirin-Triggered 15-EPI-LXA4 Inhibit Tumor Necrosis factor-1 Alpha-Initiated Neutrophil Responses and Trafficking: Novel Regulators of a Cytokine-Chemokine Axis Relevant to Periodontal Diseases”, Journal of Periodontal Research, vol. 34, No. 7, Oct. 1999, pp. 370-373.
Fiore et al., “Lipoxin Recognition Sites”,The Journal of Biological Chemistry, vol. 267, No. 23, 1992, pp. 16168-16176.
Claria, J. et al., Aspirin Triggers Previously Undescribed Bioactive Eicosanoids by Human Endothelial Cell-Leukocyte Interactions:,Proc, Nat'l Acad. Sci., vol. 92, 1995, pp. 9475-9479.
Serhan, “Lipoxins: Eicosanoids Carrying Intra- and Intercellular Messages”,Journal of Bioenergetics and Biomembranes, vol. 23, No. 1, 1991, pp. 105-122.
Mizukami, et al., “ω-Hydroxylation of Lipoxin B4by Human Neutrophil Microsomes: Identification of ω-Hydroxy Metabolite of Lipoxin B4and Catalysis by Leukotriene B4ω-Hydroxylase (cytochrome P-450LTBω)”,Biochimica et Biophysica Acta, No. 1168, 1993, pp. 87-93.
Popov, et al., “Effect of Lipoxin B on Colony-Forming Ability of Human Peripheral Blood Mononuclears in a Diffusion Chamber”, Translated fromByulleten′ Eksperimental′ noi Biologii i Meditsiny, vol. 107, No. 1, 1989, pp. 80-83.
Katoh, et al., “Renal Hemodynamic Actions of Lipoxin in Rats: A Comparative Physiological Study”,American Journal Physiology, vol. 263, 1992, pp. F436-F442.
Nigam, et al., “Lipoxin A4and Lipoxin B4Stimulate the Release but not the Oxygenation of Arachidonic Acid in Human Neutrophils: Dissociation between Lipid Remodeling and Adhesion”,Journal of Cellular Physiology, Vo. 142, 1990, pp. 512-523.
Lee, et al., “Inhibition of Leukotriene B4-Induced Neutrophil Migration by Lipoxin A4: Structure-Function Relationships”,Biochemical and Biophysical Research Communications, vol. 180, No. 3, 1991, pp. 1416-1421.
Nicolaou, et al., “Lipoxins and Related Eicosanoids: Biosynthesis, Biological Properties, and Chemical Synthesis”,Angew. Chem. Int. Ed. Engl., vol. 30, 1991, pp. 1100-1116.
Nicolaou, et al., “Total Synthesis of Novel Geometric Isomers of Lipoxin A4and Lipoxin B4”, Reprint fromThe Journal of Organic Chemistry, vol. 54, No. 23, 1989, pp. 5527-5535.
Brady, et al., “Leukotrienes Stimulate Neutrophil Adhesion to Mesangial Cells: Modulation with Lipoxins”,American Journal Physiology, vol. 259, 1990, pp. F809-F815.
Nicolaou et al., “Identification of a novel 7-cis-11-trans-lipoxin A4generated by human neutrophils: total synthesis, spasmogenic activities and comparison with other geometric isomers of lipoxins A4and B4”,Biochimica et Biophsica Acta, 1003, 1989, pp. 44-53.
Serhan et al., “Design of Lipoxin A4 Stable Analogs That Block Transmigration and Adhesion of Human Neutrophils”,Biochemistry, vol. 34, No. 44, 1995, pp. 14609-14615.
Maddox, et al., “Lipoxin A4 Stable Analogs Are Potent Mimetics That Stimulate Human Monocytes and THP-1 Cells via a G-protein-linked Lipoxin A4 Receptor”,The Journal of Biological Chemistry, vol. 272, No. 11, 1997, pp. 6972-6978.
Claria, J. “Aspirin-Triggered Lipoxins (15-epi-LX) Are Generated by the Human Lung Adenocarcinoma Cell Line (A549)- Neutrophil Interactions and Are Potent Inhibitors of Cell Proliferation”,Molecular Medicine, vol. 2, No. 5, Sep. 1996, pp. 583-596.
Badr, K.F. “15-Lipoxygenase Products as Leukotriene Antagonists: Therapeutic Potential in Glomerulonephritis”,Kidney International, vol. 42, Supp. 38, 1992, pp. S101-S108.
Dahlen, S.E. “Lipoxins and other Lipoxygenase Products with Relevance to Inflammatory Reactions in the Lung”,Annals of the New York Academy of Sciences, Advances in the Understanding and Treatment of Astham, (no date available), pp. 262-273.
Fiore, S. “The Lipoxin Biosynthetic Circuit and their Actions with Human Neutrophils”,Advances in Experimental Medicine and Biology, vol. 314, 1991, pp. 109-132.
Fiore, S, et al. “Induction of Functional Lipoxin A4 Receptors in HL-60 Cells”,Blood, vol. 81, No. 12, 1993, pp. 3395-3403.
Lederman, S. et al. “Identification of a Novel Surface Protein on Activated CD4+ T Cells that Induces Contact-Dependent B Cell Differentiation (Help)”,J. Exp. Med., vol. 175, 1992, pp. 1091-1101.
Madara, J.L. et al. “A Simple Approach to Measurement of Electrical Parameters of Cultured Epithelial Monolayers: Use in Assessing Neutrophil-Epithelial Interactions”,J. Tiss. Cult. Meth., vol. 14, 1992, pp. 209-216.
Madara, J.L. et al. “5′-Adenosine Monophosphate is the Neutrophil-derived Paracrine Factor that Elicits Chloride Secretion from T84 Intestinal Epithelial Cell Monolayers”,J. Clin. Invest., vol. 91, 1993, pp. 2320-2325.
Nash, S. et al. “Effects of Polymorphonuclear Leukocyte Transmigration on the Barrier Function of Cultured Intestinal Epithelial Monolayers”,J. Clin. Invest., vol. 80, 1987, pp. 1104-1113.
Noelle, R.J. et al., “A 39-kDa Protein on Activated Helper T Cells Binds CD40 and Transduces the Signal for Cognate Activation of B Cells ”,Proc. Natl. Acad. Sci. USA, vol. 89, 1992, pp. 6550-6554.
Parkos, C.A. et al. “Neutrophil Migration Across a Cultured Intestinal Epithelium”,J. Clin. Invest., vol. 88, 1991, pp. 1605-1612.
Parkos, C.A. et al. “Neutrophil Migration Across a Cultured Epithelial Monolayer Elicits a Biphasic Resistance Response Representing Sequential Effects on Transcellular and Paracellular Pathways”,The Journal of Cell Biology, vol. 117, No. 4, 1992, pp. 757-764.
Pettitt, T.R. et al., “Synthesis of Lipoxins and Other Lipoxygenase Products by Macrophages form the Rainbow Trout, Oncorhynchus Mykiss”,The Journal of Biological Chemistry, vol. 266, No. 14, 1991, pp. 8720-8726.
Samuelsson, B., “An Elucidation of the Arachidonic Acid Cascade Discover
Colgan Sean P.
Serhan Charles N.
Chong Yong S.
Fairman Colin L.
Fulbright & Jaworski
Rothenberger Scott D.
The Brigham and Women's Hospital, Inc.
LandOfFree
Approach to anti-microbial host defense with molecular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Approach to anti-microbial host defense with molecular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Approach to anti-microbial host defense with molecular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2679331